These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 22915061)

  • 41. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
    Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
    J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer.
    Markman M
    Gynecol Oncol; 2013 Oct; 131(1):241-5. PubMed ID: 23726888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?
    Le T; Latifah H; Jolicoeur L; Weberpals J; Faught W; Hopkins L; Fung MF
    Gynecol Oncol; 2011 Jun; 121(3):451-4. PubMed ID: 21402403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
    Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
    Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of evidence-based medicine on the decision of chemotherapy for epithelial ovarian cancer].
    Li GT
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):582-6. PubMed ID: 23141177
    [No Abstract]   [Full Text] [Related]  

  • 47. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
    Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
    Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
    Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
    Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
    Rowan K
    J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
    [No Abstract]   [Full Text] [Related]  

  • 51. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
    Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
    Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
    [No Abstract]   [Full Text] [Related]  

  • 52. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
    Fujiwara K; Markman M; Morgan M; Coleman RL
    Gynecol Oncol; 2005 Apr; 97(1):10-5. PubMed ID: 15790431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
    Kato MK; Yunokawa M; Bun S; Shimoi T; Yonemori K; Miyasaka N; Kato T; Tamura K
    J Cancer Res Clin Oncol; 2020 May; 146(5):1335-1341. PubMed ID: 32144536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Carboplatin in cancer of the ovary].
    Pujade-Lauraine E; Guastalla JP; Vincent P
    Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
    Jordan S; Steer C; DeFazio A; Quinn M; Obermair A; Friedlander M; Francis J; O'Brien S; Goss G; Wyld D; Australian Ovarian Cancer Study Group ; Webb P;
    Gynecol Oncol; 2013 May; 129(2):310-7. PubMed ID: 23403164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
    Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
    Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
    Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
    N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does severe anemia caused by dose-dense paclitaxel-Carboplatin combination therapy have an effect on the survival of patients with epithelial ovarian cancer? Retrospective analysis of the Japanese gynecologic oncology group 3016 trial.
    Kumagai S; Sugiyama T; Shoji T; Michimae H; Katsumata N; Aoki D; Terauchi F; Jobo T; Ochiai K; Yasuda M
    Int J Gynecol Cancer; 2011 Dec; 21(9):1585-91. PubMed ID: 22123713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
    Chang YH; Lu CH; Yen MS; Lee WH; Chang Y; Chang WP; Chuang CM
    Chin J Cancer; 2016 May; 35():45. PubMed ID: 27160669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.